Advertisement


Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Collyar: What's In It for Patients?

Opening Session Panel Discussion

Advertisement

Advertisement




Advertisement